Screener / SEC EDGAR /CIK 0000887359 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Vericel Corp VCEL

Compare with peers Embed
The 10-K against last year's

126 changes: 27 added, 33 removed, 61 reworded, 5 quiet changes

10-K Feb 26, 2026 vs Feb 27, 2025

10-K 0001628280-26-012013 (Feb 26, 2026) vs 10-K 0001628280-25-008447 (Feb 27, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

337 paragraphs · 24 new · 75 reworded · 27 gone · 10-K Feb 26, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 216 · 46% changed Every version of it
Disruptions at the FDA and other agencies may also slow the time necessary to review and/or approve product candidates or changes to existing products, approve the qualification of the Burlington manufacturing facility and/or conduct required inspections of our and/or third-party manufacturing and testing facilities, and approve and/or inspect third-party contractors and/or potential new or alternate suppliers of materials used in our MACI and Epicel cell manufacturing processes, all of which would adversely affect our business. For example, beginning on February 13, 2025, the U.S. government has previously shut Department of Health and Human Services began firing a large number of its probationary employees, a category that includes new federal employees and
Paragraph 46 · 45% changed Every version of it
For the year years ended December 31, 2024 2025 and 2024, we reported net income of $16.5 million and $10.4 million. million, respectively. Prior to that, with the exception of the year ended December 31, 2020, when we reported net income of $2.9 million, we had incurred net losses each year since our inception. As of December 31, 2024, we had accumulated a deficit of approximately $392.8 million and $156.1 million of cash, cash equivalents and investments. We expect that cash from the sales of our products and existing cash, cash equivalents, investments and available borrowing capacity will be sufficient to support our current operations through at least 12 months following the issuance of the consolidated financial statements included in this Annual Report on Form 10-K.
Paragraph 172 · 43% changed Every version of it
Generally, if any FDA inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulation occurs independent of such an inspection or audit, we or the FDA may require remedial measures that may be costly and/or time consuming for us or a third-party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales, recalls, warning letters, market withdrawals, seizures, placement of a non-U.S. facility on an import alert, or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.
Paragraph 140 · 42% changed Every version of it
Additionally, the escalation of hostilities instabilities and tensions in the Middle East region involving Israel, the initiation of a military conflict between Taiwan and China or the imposition or a trade embargo or blockade affecting Taiwan Israel could negatively affect MediWound’s ability to supply NexoBrid to the U.S. market. We continue to monitor the ongoing conflicts in Israel and are in close communication with MediWound leadership. MediWound’s NexoBrid manufacturing operations are continuing and, as of the date of this disclosure, MediWound does not anticipate a material disruption to its ongoing supply of commercial NexoBrid to the United States. To the extent the ongoing military conflicts in the Middle East region involving Israel intensify or expand in the region and MediWound’s facilities in Israel are damaged or destroyed, travel to and from Israel is halted or inhibited, shipments of NexoBrid or NexoBrid related materials are destroyed, or significant key MediWound operational personnel are called to military service, MediWound’s ability to continue to supply NexoBrid to the U.S. market could be disrupted.
Paragraph 126 · 42% changed Every version of it
Presently, we employ limited arrays of artificial intelligence technology in our business, the use of which may introduce us to certain risks including dependency on accurate intelligence performance, potential security breaches, challenges in regulatory compliance, ethical considerations, potential workforce disruption, the risk of intellectual property infringement, and other emerging technology risks. It is conceivable that we might integrate additional artificial intelligence solutions into our information systems in the future, potentially assuming a more critical role in our operations over time. While Additionally, while we have established policies governing the use of artificial technology, and we safeguard our assets, including intellectual property and sensitive information, we cannot ensure that our employees, contractors or other agents would adhere to those policies. Failure or perceived failure by us to address these risks adequately may negatively impact our operations, reputation and financial performance. Additionally, other unforeseen risks stemming from our use and development of artificial intelligence tools and technology may arise in the future that could adversely affect our business, financial condition and results of operations.
Paragraph 232 · 39% changed Every version of it
Given recent federal and state government initiatives directed at lowering the total cost of healthcare, the executive branch, Congress and state legislatures will likely continue to focus on healthcare reform and the reform of the Medicare and Medicaid programs. For example, on July 9, 2021, April 15, 2025, President Biden Trump issued an executive order entitled “Lowering Drug Prices by Once Again Putting Americans First,” which outlined several initiatives, including modifying the IRA’s Medicare Drug Price Negotiation Program and directing FDA to enhancing generic/biosimilar competition and drug importation. President Trump also signed another executive order intended to deliver MFN drug pricing to American patients, and CMMI subsequently proposed a voluntary model for Medicaid and mandatory models for Medicare Parts B and D to effectuate the FDA to, among other things, continue to clarify and improve the approval framework for biosimilars, including the standards for interchangeability of biological products, facilitate the development and approval of biosimilar and interchangeable products, clarify existing requirements and procedures related to the review and submission of BLAs, and identify and address any efforts to impede biosimilar competition. order. While we cannot predict the full outcome of any such government action or legislation, it may harm our ability to market our products and generate revenues.
Paragraph 327 · 39% changed Every version of it
U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions due, in part, to the conflicts in Ukraine and the Middle East region involving Israel. Although the length and impact of the ongoing conflict in Ukraine and the Middle East region is highly unpredictable, the geopolitical uncertainty caused by the conflicts has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has contributed to sustained high levels of inflation globally. Although inflation has moderated slightly, it has remained persistent in the United States in recent years due, in part, to supply chain issues, elevated energy prices, labor shortages and trade policies, among other factors. We are continuing to monitor inflation, the situations in Ukraine Ukraine, the Middle East region and Israel South America and global capital markets and assessing the potential impact on our business.
Paragraph 141 · 39% changed Every version of it
Additionally, the escalation of hostilities in the Middle East region involving Israel, the initiation of a military conflict between Taiwan and China or the imposition or a trade embargo or blockade affecting Taiwan could negatively affect MediWound’s ability to supply NexoBrid to the U.S. market. We continue to monitor the ongoing conflicts in Israel and are in close communication with MediWound leadership. MediWound’s NexoBrid manufacturing operations are continuing and, as of the date of this disclosure, MediWound does not anticipate a material disruption to its ongoing supply of commercial NexoBrid to the United States. To the extent the ongoing military conflicts in the Middle East region involving Israel intensify or expand were to result in the region and damage to MediWound’s facilities in Israel are damaged or destroyed, inhibit travel or commercial shipments to and from Israel is halted or inhibited, shipments of NexoBrid or NexoBrid related materials are destroyed, or significant key MediWound operational personnel are called to military service, Israel, MediWound’s ability to continue to supply NexoBrid to the U.S. market could be disrupted. As of the date of this report, we maintain an ample supply of NexoBrid at our U.S.-based third-party logistics provider.

MD&A

60 paragraphs · 3 new · 24 reworded · 6 gone · 10-K Feb 26, 2026 against Feb 27, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 11 · 49% changed
We also are evaluating the feasibility and potential market opportunity involved in focused on delivering MACI treatment to patients suffering from cartilage damage in the ankle. We believe that this potential lifecycle enhancement and indication expansion Following an application to the FDA, we received Investigational New Drug (“IND”) clearance for MACI will require conducting an additional randomized clinical trial concerning the product’s MACI’s use in the ankle during the second quarter of 2025, and we are on track during the fourth quarter of 2025 initiated a Study of MACI in Patients Aged 17 to initiate 65 with Symptomatic Chondral or Osteochondral Defects of the Talus (“MASCOT”). MASCOT is a two-year prospective, multicenter, two-arm, parallel group open-label trial in which a total of 309 subjects, aged 17 to 65 will be randomized 2:1 to receive a one-time treatment in the talus with MACI Ankle or arthroscopic bone marrow stimulation. MASCOT is the first randomized, controlled clinical trial beginning evaluating MACI for the treatment of Osteochondral Lesion of the Talus (“OLT”). There are approximately 165,000 ankle resurfacing procedures conducted in 2025. the U.S. each year. Approximately 66,000 of those patients each year are considered clinically appropriate for MACI by surgeons. We estimate that approximately 18,000 of those patients suffer from larger ankle cartilage lesions, resulting in an increase of MACI’s addressable market. If approved, we believe MACI’s label expansion allowing its use to repair cartilage defects in the ankle will be a significant long-term growth driver for the product in the coming years.
Paragraph 33 · 43% changed
Our cash, cash equivalents, and restricted cash totaled $85.0 million, short-term investments totaled $41.7 million and long-term investments totaled $39.9 million as of December 31, 2024. The $58.2 million of net cash provided by operations in 2024, was primarily the result of net income of $10.4 million, non-cash charges of $36.5 million related to stock compensation expense, $6.7 million in operating lease amortization and $5.5 million in depreciation and amortization expense, partially offset by a net decrease of $0.7 million related to movements in our working capital accounts. The overall decrease in cash from our working capital accounts was primarily driven by an increase in inventory primarily related to supporting NexoBrid commercial availability and an increase in accounts receivable due to higher sales volume, partially offset by an increase in operating lease liabilities due to receipts of tenant improvement allowances which exceeded payments on operating leases amortization.
Paragraph 22 · 31% changed
Research and development expenses for the year ended December 31, 2024 2025 were $24.8 $27.6 million, compared to $21.0 $24.8 million for 2023. 2024. The increase is primarily related to MACI arthroscopic development program costs and an increase in additional headcount and employee expenses. expenses including to support the technical transfer of MACI to our new manufacturing facility in Burlington, Massachusetts, primarily offset by lower MACI Arthro project costs compared to 2024.
Paragraph 23 · 30% changed
Selling, general and administrative expenses for the year ended December 31, 2024 2025 were $142.8 $167.0 million, compared to $121.0 $142.8 million for 2023. 2024. The increase in selling, general and administrative expenses is primarily due to higher headcount and employee expenses, including stock compensation, an increase in employee expenses and stock compensation, the Burlington Lease which commenced in June of 2023, and additional travel, marketing programs and sales activity, and facility costs including depreciation expense for the new facility in person events across the commercial organization, including to support the MACI arthroscopic launch. Burlington, Massachusetts.
Paragraph 13 · 24% changed
Epicel is a permanent skin replacement for deep-dermal or full-thickness burns comprising greater than or equal to 30 percent TBSA. Epicel is regulated by CBER of the FDA FDA’s Center for Biologics Evaluation and Research (“CBER”) under medical device authorities, and is the only FDA-approved cultured epidermal autograft product available for large total surface area burns in both adult and pediatric patients. Epicel was designated as a HUD in 1998 and an HDE application for the product was submitted in 1999. HUDs are devices that are intended for diseases or conditions that affect fewer than 8,000 individuals annually in the U.S., and certain HUDs are restricted by the amount which a manufacturer may charge for its use.
Paragraph 53 · 22% changed
We determine if an arrangement is a lease at inception, in accordance with ASC Topic 842, Leases. Operating lease commitments with a lease term greater than 12 months are recognized as right-of-use (“ROU”) assets and liabilities, on a discounted basis on the balance sheet. Leases with an initial term of 12 months or less are not recorded on the balance sheet. We primarily enter into lease agreements for manufacturing and office space, warehouse space, and certain equipment. The leases have varying terms, some of which may include options to extend. Certain of our lease agreements include lease payments that are adjusted periodically for an index or rate. The leases are initially measured using the present value of the projected payments adjusted for the index or rate in effect at the commencement date. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Paragraph 25 · 21% changed
For the years ended December 31, 2024 2025 and 2023, 2024, we recorded $0.1 $0.9 million and $0.8 $0.1 million, respectively, of income tax expense as a result of state income taxes. This The increase in income tax expense is primarily due to the elimination of the option to deduct research and development expenditures immediately an increase in the year incurred and instead amortize such expenditures over five years for tax purposes. taxable income. We continue to maintain a full valuation allowance on all of our net deferred tax assets.
Paragraph 31 · 19% changed
Our cash, cash and cash equivalents and restricted cash totaled $86.9 $100.1 million, short-term investments totaled $40.5 $37.4 million and long-term investments totaled $25.3 $61.4 million as of December 31, 2023. 2025. The $35.3 $51.9 million of net cash provided by operations in 2023, 2025, was primarily the result of net income of $16.5 million, non-cash charges of $32.3 $38.8 million related to stock compensation expense, $6.1 million in operating lease amortization and $4.6 $11.5 million in depreciation and amortization expense, expense and $5.4 million in operating lease amortization, partially offset by a net loss of $3.2 million and a net decrease of $4.1 $22.4 million related to movements in our working capital accounts. The overall decreases decrease in cash from our working capital accounts were was primarily driven by an increase in accounts receivable due to higher sales volume and payments on operating leases, partially offset by an increase in sales volume, offset by a decrease in inventory due to usage for production needs, an increase of accounts payable and accrued expenses due to timing of payments and receipts of tenant improvement allowances which exceeded payments on operating leases amortization. payments.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors204 words changed in this paragraph; it is 47% similar to last year's version.
Our ability to conduct business can be significantly impacted by changes in tariffs, changes or repeals of trade agreements, or the imposition of other trade restrictions or retaliatory actions imposed by various governments. For example, the new U.S. presidential administration enacted new tariffs during 2025, and has proposed to additional changes in trade policy, that significantly increase increased, and that may further increase, tariffs on foreign imports into the U.S. The imposition of such tariffs have been introduced and as of February 2025, new tariffs were enacted (and are significantly evolving) that significantly increase tariffs paused on foreign imports into numerous occasions, pending negotiations with the U.S. relevant countries. Other effects of these changes, including responsive actions from governments, could also have adverse impacts on our financial results. We As a result, there continues to be significant uncertainty regarding the extent and duration of applicable tariffs, and their impact on the global economy. All of our operations are currently located in the U.S. and 100% of our revenue in 2025 was derived from U.S. sales of our products. For the next several years we expect that the vast majority of our revenue will continue to be derived from domestic sales. However, should tariffs remain in place on certain other commodities, there is potential for an adverse impact to our operating results. Nevertheless, based on the limited costs associated with imported materials, we expect that current or future tariffs will have an insignificant impact on our cost of goods sold and gross margin moving forward, but we cannot predict what further action may be taken with respect to tariffs or trade relations between the U.S. and other governments, and any further changes in U.S. or international trade policy could have an adverse impact on our business.

Source: Item 1A, 10-K 0001628280-26-012013 vs Item 1A, 10-K 0001628280-25-008447

MD&A189 words changed in this paragraph; it is 39% similar to last year's version.
We also are evaluating the feasibility and potential market opportunity involved in focused on delivering MACI treatment to patients suffering from cartilage damage in the ankle. We believe that this potential lifecycle enhancement and indication expansion Following an application to the FDA, we received Investigational New Drug (“IND”) clearance for MACI will require conducting an additional randomized clinical trial concerning the product’s MACI’s use in the ankle during the second quarter of 2025, and we are on track during the fourth quarter of 2025 initiated a Study of MACI in Patients Aged 17 to initiate 65 with Symptomatic Chondral or Osteochondral Defects of the Talus (“MASCOT”). MASCOT is a two-year prospective, multicenter, two-arm, parallel group open-label trial in which a total of 309 subjects, aged 17 to 65 will be randomized 2:1 to receive a one-time treatment in the talus with MACI Ankle or arthroscopic bone marrow stimulation. MASCOT is the first randomized, controlled clinical trial beginning evaluating MACI for the treatment of Osteochondral Lesion of the Talus (“OLT”). There are approximately 165,000 ankle resurfacing procedures conducted in 2025. the U.S. each year. Approximately 66,000 of those patients each year are considered clinically appropriate for MACI by surgeons. We estimate that approximately 18,000 of those patients suffer from larger ankle cartilage lesions, resulting in an increase of MACI’s addressable market. If approved, we believe MACI’s label expansion allowing its use to repair cartilage defects in the ankle will be a significant long-term growth driver for the product in the coming years.

Source: Item 7, 10-K 0001628280-26-012013 vs Item 7, 10-K 0001628280-25-008447

Accounting Policies164 words changed in this paragraph; it is 34% similar to last year's version.
In November 2023, September 2025, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to Reportable Segment Disclosures, the Accounting for Internal-Use Software. The standard removes all references to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The disclosure requirements must software development stages. It also requires that an entity capitalizes software when both: (1) management has authorized and committed funding to the project and (2) it is probable that the project will be applied retrospectively completed and the software is used to all prior perform the intended function. This ASU may be adopted prospectively, retrospectively, or on a modified transition approach based on the status of the project and whether software costs were capitalized before the date of adoption. It is effective for annual periods presented in the financial statements. The effective date for the standard is for fiscal years beginning after December 15, 2023 2027 and interim periods within fiscal years beginning after December 15, 2024, 2027 with early adoption permitted. The Company adopted ASU 2023-07 as of December 31, 2024 and is currently evaluating the adoption impact of this standard is disclosed in guidance on the footnotes of the Company’s consolidated financial statements. statements and disclosures.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001628280-26-012013 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001628280-25-008447

Legal Proceedings4 words changed in this paragraph; it is 99% similar to last year's version.
From time-to-time, time to time, the Company could be a party to various legal proceedings arising in the ordinary course of business. The costs and outcome of litigation, regulatory, investigatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.

Source: Item 3, via Note 14 – Commitments and Contingencies, 10-K 0001628280-26-012013 vs Item 3, via Note 14 – Commitments and Contingencies, 10-K 0001628280-25-008447

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of VCEL's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Feb 27, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
•If we do not effectively expand and train our direct sales force, we may be unable to add new customers or increase sales to our existing customers, and our business will be adversely affected.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•Expansion into international markets is expected to be an aspect of our long-term growth, and as we expand internationally, we will face additional business, political, legal, regulatory, operational, financial, and economic risks, any of which could increase our costs and hinder such growth.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Market acceptance of any future product candidates (including MACI Ankle, for which we initiated a clinical trial in the fourth quarter of 2025), if approved, will not be fully known until after they are launched and may be negatively affected by a
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
If we do not effectively expand and train our direct sales force, we may be unable to add new customers or increase sales to our existing customers, and our business will be adversely affected.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
During 2025, we began an expansion of our MACI sales force. Our ability to achieve significant revenue growth will depend, in large part, on our success in recruiting, training and retaining sufficient numbers of sales personnel. We have expanded our sales organization significantly in recent periods and may do so again in the future. There is significant competition for sales personnel with the skills and technical knowledge that we require. New hires require significant training and may take significant time before they achieve full productivity. Our recent hires and potential future hires may not become productive as quickly as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals in the markets where we do business or plan to do business. In addition, some members of our sales force are new to our company and selling our products, and therefore may be less effective than our more seasoned sales personnel. Furthermore, hiring sales personnel in new territories and regions, or expanding our existing presence, requires upfront and ongoing expenditures that we may not recover if the sales personnel fail to achieve full productivity. We cannot predict whether, or to what extent, our sales will increase as we expand our sales force or how long it will take for sales personnel to become productive. If we are unable to hire and train a sufficient number of effective sales personnel, or the sales personnel we hire are not successful in obtaining new customers or increasing sales to our existing customer base, our business and results of operations will be adversely affected.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Expansion into international markets is an aspect of our long-term growth, and as we expand internationally, we will face additional business, political, legal, regulatory, operational, financial, and economic risks, any of which could increase our costs and hinder such growth.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
Expanding our business to attract customers in countries other than the United States is an element of our long-term business strategy. For example, we have initiated a staged approach to expanding our MACI operations outside of the U.S. and initially into the United Kingdom. Conducting business internationally involves a number of risks, including:
Read it in 10-K Feb 26, 2026 at sec.gov
Show the other 54
AddedRisk Factors
•multiple, conflicting and changing laws and regulations such as tax laws, privacy and data protection laws and regulations, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
•natural disasters, political and economic instability, including wars, terrorism, social or political unrest, including civil unrest, protests, and other public demonstrations, outbreaks of disease, pandemics or epidemics, boycotts, curtailment of trade, and other market restrictions;
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
We are subject to public health crises, which have had and may in the future have a significant impact on our operations, cash flows and liquidity. The response to a public health crisis may affect the global economy, disrupt global supply chains, and create significant disruption in financial and healthcare markets, including U.S. staffing shortages, our ability to access customers, and significant volatility in our results of operations due to the periodic cancellation or delay of elective MACI surgical procedures. Uncertainty caused by pandemics, epidemics, or other similar public health crises could lead to prolonged economic downturns and reduce or delay demand for our products, in which case our results of operations could be significantly impacted. The extent to which a public health crisis impacts our business, results of operations, and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including the timing or effectiveness of vaccine roll-outs globally, the timing of easing of preventative or mitigation measures or mandates, the impact of any variants that emerge, or any impact of a global vaccine roll-out on the global economy.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
EU regulation also governs our business. For example, in 2016, the EU adopted a new regulation governing data practices and privacy called the General Data Protection Regulation (“GDPR”), which became effective on May 25, 2018. The GDPR applies to any company established in the EU as well as to those outside the EU if they collect and use personal data in
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
We face competition in the markets targeted by our products. Many of our competitors have substantially greater resources than we do, and we expect that all of our products will face competition from existing or future products, which may impact our ability to successfully commercialize our products.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
All of our products face competition from other surgical procedures as well as existing and future products marketed by large companies. These competitors may successfully market products that compete with our products, identify and bring to market new product candidates earlier than we do, or develop products that are more effective or less costly than our products. These competitive factors could require us to conduct substantial new research and development activities to establish new product targets, which would be costly and time consuming. These activities can adversely impact our ability to effectively commercialize products and achieve revenue and profits.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Further, geopolitical tensions between Taiwan and China have risen steadily over the past year. Although Taiwan has been governed independently from China since 1949, China views Taiwan as part of its territory and has vowed to eventually unify Taiwan with China, using military force if necessary. War or other military conflict in or near Taiwan, pandemics, and certain natural disasters, such as earthquakes, which are commonplace in Taiwan (where CBC is located) may result in the destruction or disruption of CBC’s ability to supply Bromelain SP to MediWound and have downstream implications for our Company.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
For example, we are currently evaluating the feasibility and potential market opportunity involved in delivering MACI treatment to patients suffering from cartilage damage in the ankle. We believe that this potential lifecycle enhancement and indication expansion for MACI will require conducting an additional randomized clinical trial concerning the product’s use in the ankle. We conducted pre-IND interactions with the FDA concerning our clinical development program for MACI to treat cartilage injuries in the ankle, and based on feedback from the FDA, our team is actively working to finalize our non-clinical testing and propose a clinical development plan/protocol to FDA for review. We are on track to initiate a MACI Ankle clinical trial later in 2025.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
down and has nearly shut down several times in recent years. During previous shutdowns, certain regulatory agencies, including the FDA, have had to furlough essential employees and stop critical activities. If a prolonged government shutdown occurs in the future, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
Furthermore, there have been and continue to be a number of initiatives at the federal and state levels that seek to reduce healthcare costs. In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act of 2010, as
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
amended by the Health Care and Education Reconciliation Act (jointly, the ACA), which includes measures to significantly change the way health care is financed by both governmental and private insurers.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
also involve the improper use of information obtained in the course of patient recruitment for clinical trials. See the section entitled, “Business — Government Regulation — Other Healthcare Laws”.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedRisk Factors
competitive advantage, and MediWound may be unable to adequately develop new technologies and obtain future patent protection to preserve our competitive advantage or avoid adverse effects on our business.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedRisk Factors
Generally, if any FDA inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulation occurs independent of such an inspection or audit, we or the FDA may require remedial measures that may be costly and/or time consuming for us or a third-party to implement and that may include the temporary or permanent suspension of a clinical trial or commercial sales, recalls, warning letters, market withdrawals, seizures, placement of a non-U.S. facility on an import alert, or the temporary or permanent closure of a facility.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
To the extent the ongoing military conflicts in the Middle East region involving Israel intensify or expand were to result in the region and damage to MediWound’s facilities in Israel are damaged or destroyed, inhibit travel or commercial shipments to and from Israel is halted or inhibited, shipments of NexoBrid or NexoBrid related materials are destroyed, or significant key MediWound operational personnel are called to military service, Israel, MediWound’s ability to continue to supply NexoBrid to the U.S. market could be disrupted.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Disruptions at the FDA and other agencies may also slow the time necessary to review and/or approve product candidates or changes to existing products, approve the qualification of the Burlington manufacturing facility and/or conduct required inspections of our and/or third-party manufacturing and testing facilities, and approve and/or inspect third-party contractors and/or potential new or alternate suppliers of materials used in our MACI and Epicel cell manufacturing processes, all of which would adversely affect our business.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If the technology that we use infringes a patent held by others, or if the technology utilized by MediWound in development and manufacturing NexoBrid infringes another’s patent, we could be sued for monetary damages by the patent holder or its licensee, or we could be prevented from continuing research, development, and commercialization of products that rely on that technology, unless a license is obtained to use the patent.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Finally, if we are unable to continue to develop and market new products and technologies (such as MACI Arthro) in a timely manner, the demand for our recently products may decrease or our products could become obsolete, and our revenue may decline or our growth prospects may be adversely affected.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If any of our manufacturers or suppliers fails to perform its respective obligations, or if our supply of certain components, equipment, disposable devices and other materials is limited or interrupted, it could impair our ability to manufacture our products, which would delay our ability to market our commercial products or future product candidates or conduct clinical trials on a timely and cost-competitive basis, if at all.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Although the length and impact of the ongoing conflict conflicts in Ukraine and the Middle East region is and political and military developments in South America are highly unpredictable, the geopolitical uncertainty caused by the conflicts and developments has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has contributed to sustained high levels of inflation globally.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
In the last year, the The FTC has announced that it will begin enforcing the Health Breach Notification Rule, and has entered into at least one consent order with a different organization that involved a $1.5 million fine. enforced the Rule several times.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Further, navigating continually evolving legal and regulatory requirements associated with implementing artificial intelligence tools that may be inconsistent from jurisdiction to jurisdiction may require significant resources to help ensure compliance with U.S. law. law or various international laws or limit our ability to incorporate certain artificial intelligence capabilities into our operations.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Additionally, the escalation of hostilities instabilities and tensions in the Middle East region involving Israel, the initiation of a military conflict between Taiwan and China or the imposition or a trade embargo or blockade affecting Taiwan Israel could negatively affect MediWound’s ability to supply NexoBrid to the U.S. market.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, ongoing conflict between conflicts in Russia and Ukraine and the ongoing conflicts in the Middle East region involving Israel, Region and political and military developments in South America, and sustained high levels of inflation.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Although, to date, our business has not been materially impacted by the ongoing military conflict between conflicts in Russia and Ukraine or the ongoing conflict in the Middle East region, region or the political and military developments in South America, geopolitical tensions, or sustained high levels of inflation, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which such matters may impact our business.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
Finally, our Burlington facility, discussed more fully above, is designed to meet both U.S. and global manufacturing requirements, which provides strategic flexibility to potentially commercialize MACI outside the U.S., and we are currently evaluating introducing MACI in additional geographies. We are currently focused on obtaining regulatory and marketing approval for MACI in the United Kingdom through the Medicine and Healthcare products Regulatory Agency (“MHRA”) and, if successful, anticipate commercializing MACI in the United Kingdom in 2027.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
submitted in 1999. HUDs are devices that are intended for diseases or conditions that affect fewer than 8,000 individuals annually in the U.S., and, for certain HUDs, the amount a manufacturer may charge for the product’s use is restricted.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
by pooling accounts receivable based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
See “Risk Factors “Our success depends, in part, on the commercial success of NexoBrid for the removal of eschar in adults with deep partial thickness and/or full thickness thermal burns.”
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
In May 2019, we entered into exclusive license and supply agreements with MediWound, under which MediWound manufactures and supplies NexoBrid to the U.S. market on a unit price basis. MediWound develops and manufactures NexoBrid, in part, at its facilities in Yavne, Israel.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
We continue to monitor the ongoing conflicts in the Middle East region involving Israel, and we are in close communication with MediWound leadership. MediWound’s NexoBrid manufacturing operations are continuing and, as of the date of this disclosure, MediWound does not anticipate a material disruption to its ongoing supply of commercial NexoBrid to the United States. To the extent the conflicts in the Middle East region intensify or expand and MediWound’s facilities in Israel are damaged or destroyed, travel to and from Israel is halted or inhibited, or significant key MediWound operational personnel are called to military service, MediWound’s ability to continue to supply NexoBrid to the U.S. market could be disrupted. As of the date of this report, we maintain an ample supply of NexoBrid at our U.S.-based third-party logistics provider.
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
The following table summarizes research and development expenses, which include materials, professional fees and an allocation of employee-related salary and fringe benefit costs for our research and development projects:
Read it in 10-K Feb 27, 2025 at sec.gov
RemovedMD&A
In April 2023, in connection with the Burlington Lease, we entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023 we began funding into an escrow account maintained by the escrow agent a portion of our share of tenant improvement construction costs at the facility, which is designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. The Company funded the remaining 50% of its required cost amount, or approximately $28.3 million, with cash on hand, pursuant to the Construction Escrow Agreement in April 2024. Additionally, and in order to support the expansion of our autologous cell manufacturing operations at the new facility in Burlington, we have and continue to invest in the acquisition and installation of certain specialized manufacturing and laboratory equipment.
Read it in 10-K Feb 27, 2025 at sec.gov
RewordedMD&A
The overall decreases decrease in cash from our working capital accounts were was primarily driven by an increase in accounts receivable due to higher sales volume and payments on operating leases, partially offset by an increase in sales volume, offset by a decrease in inventory due to usage for production needs, an increase of accounts payable and accrued expenses due to timing of payments and receipts of tenant improvement allowances which exceeded payments on operating leases amortization. payments.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The $35.3 $51.9 million of net cash provided by operations in 2023, 2025, was primarily the result of net income of $16.5 million, non-cash charges of $32.3 $38.8 million related to stock compensation expense, $6.1 million in operating lease amortization and $4.6 $11.5 million in depreciation and amortization expense, expense and $5.4 million in operating lease amortization, partially offset by a net loss of $3.2 million and a net decrease of $4.1 $22.4 million related to movements in our working capital accounts.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The overall decrease in cash from our working capital accounts was primarily driven by an increase in inventory primarily related to supporting NexoBrid commercial availability and an increase in accounts receivable due to higher sales volume, partially offset by an increase in operating lease liabilities due to receipts of tenant improvement allowances which exceeded payments on operating leases amortization.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our portfolio of commercial-stage products also includes NexoBrid (anacaulase-bcdb), a topically-administered biological orphan product containing proteolytic enzymes, for which the FDA approved a BLA in December 2022 permitting the product’s use for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. 2022.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Total revenue increase for the year ended December 31, 2024, 2025, compared to 2023, 2024, was driven primarily by MACI volume and price growth, in addition to higher Epicel growth and NexoBrid volume growth, partially offset by lower Epicel volume.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 Net cash provided by operating activities $ 51,910 $ 58,163 $ 35,311 $ 17,687 Net cash used in investment activities (43,937) (79,034) (3,130) (36,206) Net cash provided by financing activities 7,070 19,054 3,618 1,045 Net increase (decrease) increase in cash, cash equivalents, and restricted cash $ 15,043 $ (1,817) $ 35,799 $ (17,474)
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our cash, cash and cash equivalents and restricted cash totaled $86.9 $100.1 million, short-term investments totaled $40.5 $37.4 million and long-term investments totaled $25.3 $61.4 million as of December 31, 2023. 2025.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Total remaining obligations related to operating and finance leases are $146.0 million, with $4.4 $132.3 million of tenant improvement allowances allowed for, as of December 31, 2024. 2025.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
In the last five years through 2024, 2025, MACI sales volumes from the first through the fourth quarter on average represented 21% (20%-22% range), 23% (22%-24% range), 22% (16%-24% range), 23% (21%-26% (21%-24% range) and 34% (33%-38% (33%-34% range) respectively, of total annual volumes.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Epicel is regulated by CBER of the FDA FDA’s Center for Biologics Evaluation and Research (“CBER”) under medical device authorities, and is the only FDA-approved cultured epidermal autograft product available for large total surface area burns in both adult and pediatric patients.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Gross profit increased for the year ended December 31, 2024, 2025, compared to the same period in 2023, 2024, primarily driven by MACI revenue growth across all products, combined with our primarily fixed manufacturing cost structure, which consists mainly of labor and facility costs.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesMD&A
The arthroscopic delivery of MACI could may increase the ease of MACI’s use for physicians and may reduce both the length of the procedure as well as procedure-induced trauma, which may result in a reduction of a patient’s post-operative pain and accelerate a patient’s recovery.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesMD&A
NexoBrid’s FDA approval expands our burn care franchise’s total addressable market, which will permit permits us to treat a significantly larger segment of hospitalized burn patients than with Epicel alone.
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCEL/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.